In the rapidly evolving realm of biotechnology and pharmaceutical research, the pursuit of innovative solutions often hinges on robust computational infrastructure and cutting-edge technology. A trailblazer in the field of spatial biology, OMAPiX has emerged as a key player in enabling research for pharma and academic customers to unravel the complexities of cellular interactions within tissue samples. Today marks a significant milestone in OMAPiX’s journey as the company moves to Oracle Cloud Infrastructure (OCI), establishing a strategic collaboration to propel its mission of accelerating drug discovery and development.
OMAPiX and OCI
Specializing in partnering with research and pharma stakeholders, OMAPiX, as a technology partner, is dedicated to design, run, and analyze spatial omics projects that shed light on the intricate dynamics of cellular behavior within tissues, notably tumors. This advanced approach allows for the visualization of differential gene or protein expression between individual cells within a spatial context, offering invaluable insights into disease mechanisms and treatment efficacy.
Through its collaboration with OCI, OMAPiX aims to usher in a new era of efficiency and scalability in spatial biology research. Utilizing OCI’s powerful infrastructure and scalable GPU-accelerated computing, OMAPiX can analyze vast datasets with unprecedented speed and precision, laying the groundwork for supporting discoveries in drug discovery and development. Key strategic initiatives facilitated by OCI are OMAPiX’s efforts towards building multimodal and multilayered data structures from clinical samples that could enable the identification of novel spatial signatures predictive of patient response to precision therapies such as antibody-drug conjugate therapy, as well as cell and gene therapy.
By harnessing OCI’s robust database technologies, including Oracle Application Express (APEX), OMAPiX is using its curated database to build a quarriable registry that can serve as a valuable resource for pharma customers seeking to accelerate their research and development efforts. With its domain expertise in design and development of registries, the APEX team has helped move the needle from idea to product. This innovative model not only enhances the accessibility of spatial biology data but also fosters deeper collaboration and faster insights for pharmaceutical industry partners. OMAPiX is poised to revolutionize the landscape of spatial omics enabling the integration of artificial intelligence (AI) and machine learning (ML) models developed for targeted therapy benefiting the right patients.
“We’re excited to partner with the Oracle team as we continue to support researchers in the Pharma and Academic centers,” said Mridula Iyer, Ph.D, President, Business Operations and Business Development at OMAPiX. “With the powerful tools APEX provides and OCI’s scalable compute and storage, OMAPiX can integrate and extract biological insights from complex spatial data.”
“Working within siloes slows down discovery, as well as the development and application of interventions,” said Rebekah Butterfield, innovation scientist in Healthcare Innovation and Strategic Engineering at Oracle Health. “This partnership between Oracle and OMAPiX demonstrates how powerful it can be to join efforts across industries to speed research and enhance health. We’re very excited to join their scientific expertise with Oracle’s state-of-the-art technology to impact health research and care.”
Conclusion
OMAPiX’s partnership with OCI represents a significant step forward in its quest to revolutionize spatial biology and accelerate drug discovery. Together, OMAPiX and Oracle Cloud Infrastructure are unlocking new frontiers of innovation, empowering researchers, and pharma companies alike to harness the power of spatial biology for the advancement of human health.
To learn more, see the following resources:
